Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 201–300 of 1,008
Gasser, T., Hardy, J., & Mizuno, Y. (2011) · Movement Disorders · doi:10.1002/mds.23637 · Cited by 166
Self-citationMicroRNAs in Parkinson's disease
Mouradian, M. M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.046 · Cited by 165
The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease
Aflaki, E., Westbroek, W., & Sidransky, E. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.018 · Cited by 159
“When all exons of GBA1 were sequenced, approximately 7% of subjects with PD carried mutations in GBA1 (Sidransky et al., 2009).”
Self-citationAn updated review of Parkinson's disease genetics and clinicopathological correlations
Ferreira, M., & Massano, J. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12616 · Cited by 167
Genetics of Alzheimer's Disease
Guerreiro, R., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 155
Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages
Aflaki, E., Moaven, N., Borger, D. K., Lopez, G., Westbroek, W., Chae, J. J., Marugan, J., Patnaik, S., Maniwang, E., Gonzalez, A. N., et al. (2016) · Aging Cell · doi:10.1111/acel.12409 · Cited by 158
“Mutations in the glucocerebrosidase gene (GBA1) are an important genetic risk factor for PD and related Lewy body disorders (Sidransky et al., 2009).”
BackgroundSelf-citationGlucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hayes, M. A., Beagan, J., McLean, J. R., Izen, S. C., Perez-Torres, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.009 · Cited by 160
Rosenbloom, B., Balwani, M., Bronstein, J. M., Kolodny, E., Sathe, S., Gwosdow, A. R., Taylor, J. S., Cole, J. A., Zimran, A., & Weinreb, N. J. (2011) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2010.10.006 · Cited by 158
Modeling neurodegeneration in Caenorhabditis elegans
Caldwell, K. A., Willicott, C. W., & Caldwell, G. A. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.046110 · Cited by 179
Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
Galper, J., Dean, N. J., Pickford, R., Lewis, S. J. G., Halliday, G. M., Kim, W. S., & Dzamko, N. L. (2022) · Brain · doi:10.1093/brain/awac176 · Cited by 182
Sanchez-Martinez, A., Beavan, M., Gegg, M. E., Chau, K.-Y., Whitworth, A. J., & Schapira, A. H. V. (2016) · Scientific Reports · doi:10.1038/srep31380 · Cited by 158
The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population
Zhao, Y., Qin, L., Pan, H., Liu, Z., Jiang, L., He, Y., Zeng, Q., Zhou, X., Zhou, X., Zhou, Y., et al. (2020) · Brain · doi:10.1093/brain/awaa167 · Cited by 170
Self-citationMitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders
Plotegher, N., & Duchen, M. R. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.003 · Cited by 161
Endocytic membrane trafficking and neurodegenerative disease
Schreij, A. M. A., Fon, E. A., & McPherson, P. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2105-x · Cited by 162
α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
Mullin, S., & Schapira, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8394-x · Cited by 146
Moors, T. E., Paciotti, S., Ingrassia, A., Quadri, M., Breedveld, G., Tasegian, A., Chiasserini, D., Eusebi, P., Duran-Pacheco, G., Kremer, T., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1090-0 · Cited by 150
“Thr369Met were considered as GBA risk factors in further analyses [6, 10, 41].”
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid
Zhao, N., Attrebi, O. N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y. A., Meneses, A. D., Li, F., Shue, F., Zheng, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1809 · Cited by 156
“Although the genetic landscape of LBD is incomplete, the most replicated genetic risk factors are at the -synuclein (SNCA) and -glucocerebrosidase (GBA) loci (5, 6) and the 4 allele of the apolipoprotein E (APOE4) gene (7–12).”
BackgroundGlucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course
Setó‐Salvia, N., Pagonabarraga, J., Houlden, H., Pascual‐Sedano, B., Dols‐Icardo, O., Tucci, A., Paisán‐Ruiz, C., Campolongo, A., Antón‐Aguirre, S., Martín, I., et al. (2012) · Movement Disorders · doi:10.1002/mds.24045 · Cited by 155
Sánchez‐Fernández, E. M., Fernández, J. M. G., & Mellet, C. O. (2016) · Chemical Communications · doi:10.1039/c6cc01564f · Cited by 165
Glycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735e9a · Cited by 153
Self-citationGBA-Associated Parkinson’s Disease and Other Synucleinopathies
Gan‐Or, Z., Liong, C., & Alcalay, R. N. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0860-4 · Cited by 171
Self-citationFarfel-Becker, T., Vitner, E. B., Kelly, S. L., Bame, J. R., Duan, J., Shinder, V., Merrill, A. H., Dobrenis, K., & Futerman, A. H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt468 · Cited by 153
Kuo, S.-H., Tasset, I., Cheng, M. M., Diaz, A., Pan, M.-K., Lieberman, O. J., Hutten, S. J., Alcalay, R. N., Kim, S., Ximénez-Embún, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm6393 · Cited by 153
Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease
Abbott, S. K., Li, H., Muñoz, S. S., Knoch, B., Batterham, M., Murphy, K. E., Halliday, G. M., & Garner, B. (2014) · Movement Disorders · doi:10.1002/mds.25729 · Cited by 154
Glial phagocytic clearance in Parkinson’s disease
Tremblay, M.-E., Cookson, M. R., & Civiero, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0314-8 · Cited by 152
“Mutations in Glucocerebrosidase (GBA) gene, which codes for a lysosomal enzyme implicated in a lysosomal storage disorder (LSD) called Gaucher’s disease (GD) in the homozygous state, are common risk factors for PD [131].”
BackgroundChiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa-Akanbi, M., Chinnery, P. F., Morris, C. M., Calabresi, P., Parnetti, L., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0010-2 · Cited by 148
Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond
Shachar, T., Bianco, C. L., Recchia, A., Wiessner, C., Raas‐Rothschild, A., & Futerman, A. H. (2011) · Movement Disorders · doi:10.1002/mds.23774 · Cited by 150
Neuronal autophagy and mitophagy in Parkinson's disease
Lizama, B. N., & Chu, C. T. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100972 · Cited by 160
The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders
Velayati, A., Yu, W. H., & Sidransky, E. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0102-x · Cited by 145
“Among Ashkenazi Jews, N370S and L444P were detected in 15% of patients and 3% of controls, whereas in patients with PD from other ethnic groups, the combined frequency of one of these two mutations was 3%.”
BackgroundMethodSelf-citationGP2: The Global Parkinson's Genetics Program
Program, T. G. P. G. (2021) · Movement Disorders · doi:10.1002/mds.28494 · Cited by 158
Chahine, L. M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D., Horn, S., Colcher, A., Hurtig, H. I., Lee, V. M.-Y., Van Deerlin, V. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1274 · Cited by 150
Self-citationC. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease
Harrington, A. J., Hamamichi, S., Caldwell, G. A., & Caldwell, K. A. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22231 · Cited by 174
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Graham, A.-R., Brown, E., McLean, J. R., Hayes, M. A., Beagan, J., Izen, S. C., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6307 · Cited by 145
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult
Henderson, M. X., Sedor, S., McGeary, I., Cornblath, E. J., Peng, C., Riddle, D. M., Li, H. L., Zhang, B., Brown, H. J., Olufemi, M. F., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.004 · Cited by 146
“Graphical Abstract Keywords GBA1; GCase; glucosylceramide; glucosylsphingosine; Parkinson’s disease; Lewy body; neurodegenerative disease; transmission; network model; misfolding; vulnerability; D409V INTRODUCTION Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) comprise two points on a spectrum of movemen…”
BackgroundResultInfluentialThe role of saposin C in Gaucher disease
Tamargo, R. J., Velayati, A., Goldin, E., & Sidransky, E. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.04.024 · Cited by 140
Self-citationDuran, R., Mencacci, N. E., Angeli, A. V., Shoai, M., Deas, E., Houlden, H., Mehta, A., Hughes, D., Cox, T. M., Deegan, P., et al. (2013) · Movement Disorders · doi:10.1002/mds.25248 · Cited by 146
Glucocerebrosidase is shaking up the synucleinopathies
Siebert, M., Sidransky, E., & Westbroek, W. (2014) · Brain · doi:10.1093/brain/awu002 · Cited by 147
Self-citationSchultheis, P. J., Fleming, S. M., Clippinger, A. K., Lewis, J., Tsunemi, T., Giasson, B., Dickson, D. W., Mazzulli, J. R., Bardgett, M. E., Haik, K. L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt057 · Cited by 143
“For example, mutations in GCase cause Gaucher’s disease, a rare inherited lysosomal storage disorder, and are the most common genetic risk factor for PD (50,51).”
BackgroundSelf-citationGrabowski, G. A., Zimran, A., & Ida, H. (2015) · American Journal of Hematology · doi:10.1002/ajh.24063 · Cited by 158
Exploring the link between glucocerebrosidase mutations and parkinsonism
Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 145
Self-citationYoung-onset Parkinson's disease: Its unique features and their impact on quality of life
Mehanna, R., & Jankovic, J. J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.06.001 · Cited by 165
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease
Koeglsperger, T., Rumpf, S.-L., Schließer, P., Struebing, F. L., Brendel, M., Levin, J., Trenkwalder, C., Höglinger, G. U., & Herms, J. W. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00622-7 · Cited by 159
Exome sequencing: a transformative technology
Singleton, A. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70196-x · Cited by 167
Self-citationGaucher Disease: Clinical, Biological and Therapeutic Aspects
Dandana, A., Khelifa, S. B., Chahed, H., Miled, A., & Ferchichi, S. (2015) · Pathobiology · doi:10.1159/000440865 · Cited by 146
Recent advances in the diagnosis and management of Gaucher disease
Gary, S. E., Ryan, E., Steward, A., & Sidransky, E. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1445524 · Cited by 149
Self-citationQuadri, M., Mandemakers, W., Grochowska, M. M., Masius, R., Geut, H., Fabrizio, E., Breedveld, G. J., Kuipers, D., Minneboo, M., Vergouw, L. J. M., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30179-0 · Cited by 143
Self-citationNo evidence for substrate accumulation in Parkinson brains with GBA mutations
Gegg, M. E., Sweet, L., Wang, B. H., Shihabuddin, L. S., Sardi, S. P., & Schapira, A. H. V. (2015) · Movement Disorders · doi:10.1002/mds.26278 · Cited by 136
Exploring Sphingolipid Implications in Neurodegeneration
Alessenko, A. V., & Albi, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00437 · Cited by 141
“The two most common mutations were identified in patients of all ethnic groups (71).”
BackgroundCreation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research
Wray, S., Self, M., NINDS Parkinson's Disease iPSC Consortium, NINDS Huntington's Disease iPSC Consortium, NINDS ALS iPSC Consortium, Lewis, P. A., Taanman, J.-W., Ryan, N. S., Mahoney, C. J., Liang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043099 · Cited by 138
Self-citationHeterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism
Puschmann, A., Fiesel, F. C., Caulfield, T. R., Hudec, R., Ando, M., Truban, D., Hou, X., Ogaki, K., Heckman, M. G., James, E. D., et al. (2017) · Brain · doi:10.1093/brain/aww261 · Cited by 138
Self-citationLin, K.-J., Lin, K.-L., Chen, S.-D., Liou, C.-W., Chuang, Y.-C., Lin, H.-Y., & Lin, T.-K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215312 · Cited by 139
Petrucci, S., Ginevrino, M., Trezzi, I., Monfrini, E., Ricciardi, L., Albanese, A., Avenali, M., Barone, P., Bentivoglio, A. R., Bonifati, V., et al. (2020) · Movement Disorders · doi:10.1002/mds.28195 · Cited by 153
“28195 Heterozygous variants in the GBA gene, encoding the lysosomal enzyme β-glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson’s disease (PD) worldwide.(1-5)”
BackgroundThe clinical management of type 2 Gaucher disease
Weiss, K., Gonzalez, A. N., Lopez, G. J., Pedoeim, L., Groden, C. A., & Sidransky, E. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.008 · Cited by 151
Self-citationThe Emerging Role of the Lysosome in Parkinson’s Disease
Navarro-Romero, A., Montpeyó, M., & Martinez-Vicente, M. (2020) · Cells · doi:10.3390/cells9112399 · Cited by 135
“Furthermore„ different evidence has linked LSDs with PD: (1) neurodegeneration is one of the main features of LDSs [2]; (2) parkinsonism has been reported in some patients with different LSDs [151,156,157]; (3) an increased risk of PD has been well established in Gaucher’s disease [39,40], and it has been suggested in…”
BackgroundInfluentialYan, S., Jiang, C., Janzen, A., Barber, T. R., Seger, A., Sommerauer, M., Davis, J. J., MAREK, K. L., Hu, M. T., Oertel, W. H., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4398 · Cited by 145
Xu, Y. H., Sun, Y., Ran, H., Quinn, B., Witte, D., & Grabowski, G. A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.12.014 · Cited by 136
Jin, S.-G., Zhang, Z.-M., Dunwell, T. L., Harter, M. R., Wu, X., Johnson, J., Li, Z., Liu, J., Szabó, P. E., Lu, Q., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.044 · Cited by 138
Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics
Senkevich, K., & Gan-Or, Z. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.11.015 · Cited by 132
Self-citationEthnic Variation in the Manifestation of Parkinson’s Disease: A Narrative Review
Ben-Joseph, A., Marshall, C. R., Lees, A. J., & Noyce, A. J. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191763 · Cited by 153
“Variation in the GBA gene is associated with an increase in the risk of PD and a reduction in the age of onset of PD in patients who carry risk variants [132, 133].”
Backgroundvan Kruining, D., Luo, Q., van Echten-Deckert, G., Mielke, M. M., Bowman, A., Ellis, S., Oliveira, T. G., & Martinez-Martinez, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.009 · Cited by 135
“Glucocerebrosidase (GBA, the enzyme breaking down GlcCer into glucose and ceramide) has been implicated in sporadic PD and Lewy Body Dementia since mutations in the gene coding for this enzyme is one of the most established genetic risk factors for these diseases [104].”
BackgroundClinical and Imaging Markers of Prodromal Parkinson's Disease
Hustad, E., & Aasly, J. O. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00395 · Cited by 147
Self-citationModels of α-synuclein aggregation in Parkinson’s disease
Giráldez-Pérez, R. M., Antolín-Vallespín, M., Muñoz, M. D., & Sánchez-Capelo, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0176-9 · Cited by 132
The role of monogenic genes in idiopathic Parkinson’s disease
Reed, X., Bandrés-Ciga, S., Blauwendraat, C., & Cookson, M. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.012 · Cited by 129
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Stoddard-Bennett, T., & Reijo Pera, R. (2019) · Cells · doi:10.3390/cells8010026 · Cited by 127
“GBA mutations have been proven in 2009 to be the most common genetic risk factor for PD so far—present in 3–7% of idiopathic PD cases [30].”
BackgroundDomingo, A., & Klein, C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00014-2 · Cited by 154
Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
Malek, N., Weil, R. S., Bresner, C., Lawton, M. A., Grosset, K. A., Tan, M., Bajaj, N., Barker, R. A., Burn, D. J., Foltynie, T., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317348 · Cited by 133
Role of Mendelian genes in “sporadic” Parkinson's disease
Lesage, S., & Brice, A. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70022-0 · Cited by 153
Self-citationParkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene
Thaler, A., Bregman, N., Gurevich, T., Shiner, T., Dror, Y., Zmira, O., Gan‐Or, Z., Bar‐Shira, A., Gana‐Weisz, M., Orr‐Urtreger, A., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.009 · Cited by 141
Self-citationEmerging Treatment Approaches for Parkinson’s Disease
Stoker, T. B., Torsney, K., & Barker, R. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00693 · Cited by 151
GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder
Gan‐Or, Z., Mirelman, A., Postuma, R. B., Arnulf, I., Bar‐Shira, A., Dauvilliers, Y. A., Désautels, A., Gagnon, J., Leblond, C. S., Frauscher, B., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.228 · Cited by 133
Self-citationGenetics of Parkinson's disease: the yield
Spatola, M., & Wider, C. W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70011-7 · Cited by 133
Yun, S. P., Kim, D., Kim, S., Kim, S., Karuppagounder, S. S., Kwon, S.-H., Lee, S., Kam, T.-I., Lee, S., Ham, S., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0233-5 · Cited by 134
Gaucher disease and other storage disorders
Grabowski, G. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.13.3797921 · Cited by 152
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Du, T.-T., Wang, L., Duan, C.-L., Lu, L.-L., Zhang, J.-L., Gao, G., Qiu, X.-B., Wang, X.-M., & Yang, H. (2015) · Autophagy · doi:10.1080/15548627.2015.1086055 · Cited by 129
Glucocerebrosidase Mutations in Parkinson Disease
O’Regan, G., deSouza, R.-M., Balestrino, R., & Schapira, A. H. (2017) · Journal of Parkinson's Disease · doi:10.3233/jpd-171092 · Cited by 127
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases
Coughlin, D. G., Hurtig, H. I., & Irwin, D. J. (2020) · Movement Disorders · doi:10.1002/mds.27867 · Cited by 124
“GBA mutations have been associated with earlier-onset PD and a more rapidly progressive clinical course with a 6-fold higher risk of dementia.(17,201,232-234) Autopsy data show relatively greater neocortical synucleinopathy burdens in patients withGBAmutations than sporadic PDwith variable rates of AD copathology.”
BackgroundClassification of GBA1 Variants in Parkinson's Disease: The GBA1 ‐PD Browser
Parlar, S. C., Grenn, F. P., Kim, J. J., Blauwendraat, C., & Gan‐Or, Z. (2023) · Movement Disorders · doi:10.1002/mds.29314 · Cited by 147
Self-citationKeatinge, M., Bui, H., Menke, A., Chen, Y.-C., Sokol, A. M., Bai, Q., Ellett, F., Da Costa, M., Burke, D., Gegg, M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv369 · Cited by 129
Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O., & Hallett, P. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.013 · Cited by 124
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
Atashrazm, F., Hammond, D., Perera, G., Dobson-Stone, C., Mueller, N., Pickford, R., Kim, W. S., Kwok, J. B., Lewis, S. J. G., Halliday, G. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33921-x · Cited by 125
Sphingolipids in the Pathogenesis of Parkinson’s Disease and Parkinsonism
Lin, G., Wang, L., Marcogliese, P. C., & Bellen, H. J. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.11.003 · Cited by 126
“Recessive mutations in GBA cause GD, while heterozygous GBA carriers have a fivefold increased risk of developing PD [10].”
BackgroundMorabito, G., Giannelli, S. G., Ordazzo, G., Bido, S., Castoldi, V., Indrigo, M., Cabassi, T., Cattaneo, S., Luoni, M., Cancellieri, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.004 · Cited by 126
de la Mata, M., Cotán, D., Oropesa-Ávila, M., Garrido-Maraver, J., Cordero, M. D., Villanueva Paz, M., Delgado Pavón, A., Alcocer-Gómez, E., de Lavera, I., Ybot-González, P., et al. (2015) · Scientific Reports · doi:10.1038/srep10903 · Cited by 126
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs
Aflaki, E., Stubblefield, B. K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008659 · Cited by 126
Self-citationThe role of glucocerebrosidase in Parkinson disease pathogenesis
Gegg, M. E., & Schapira, A. H. V. (2018) · The FEBS Journal · doi:10.1111/febs.14393 · Cited by 123
Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
Wong, Y. C., Luk, K., Purtell, K., Burke Nanni, S., Stoessl, A. J., Trudeau, L., Yue, Z., Krainc, D., Oertel, W., Obeso, J. A., et al. (2019) · Movement Disorders · doi:10.1002/mds.27823 · Cited by 122
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
García‐Sanz, P., M.F.G. Aerts, J., & Moratalla, R. (2021) · Movement Disorders · doi:10.1002/mds.28396 · Cited by 124
“disorder, hallucinations, depression and anxiety, and often, cognitive impairment and dementia.(41,48-50) A clear relationship between residual GCase activity of particular GBA1 mutations and PD risk has not been unequivocally documented.”
BackgroundMotor subtype in Parkinson's disease: Different disorders or different stages of disease?
Nutt, J. G. (2016) · Movement Disorders · doi:10.1002/mds.26657 · Cited by 132
Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease
Brás, J., Guerreiro, R. J., & Hardy, J. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3271 · Cited by 147
Lysosome‐dependent pathways as a unifying theme in Parkinson's disease
Tofaris, G. K. (2012) · Movement Disorders · doi:10.1002/mds.25136 · Cited by 118
Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
Migdalska‐Richards, A., Ko, W. K. D., Li, Q., Bezard, E., & Schapira, A. H. V. (2017) · Synapse · doi:10.1002/syn.21967 · Cited by 119
Phosphorylation of Parkin at serine 65 is essential for its activation in vivo
McWilliams, T. G., Barini, E., Pohjolan-Pirhonen, R., Brooks, S. P., Singh, F., Burel, S., Balk, K., Kumar, A., Montava-Garriga, L., Prescott, A. R., et al. (2018) · Open Biology · doi:10.1098/rsob.180108 · Cited by 116
α-Synuclein in Parkinson’s disease: causal or bystander?
Riederer, P. F., Berg, D., Casadei, N., Cheng, F., Claßen, J., Dresel, C., Jost, W. H., Krüger, R., Müller, T., Reichmann, H., et al. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02025-9 · Cited by 130
Self-citationA novel common variant in DCST2 is associated with length in early life and height in adulthood
van der Valk, R. J. P., Kreiner-Møller, E., Kooijman, M. N., Guxens, M., Stergiakouli, E., Sääf, A., Bradfield, J. P., Geller, F., Hayes, M. G., Cousminer, D. L., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu510 · Cited by 120
Farfel-Becker, T., Vitner, E. B., Pressey, S. N. R., Eilam, R., Cooper, J. D., & Futerman, A. H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr019 · Cited by 119
Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation
Fishbein, I., Kuo, Y.-M., Giasson, B. I., & Nussbaum, R. L. (2014) · Brain · doi:10.1093/brain/awu291 · Cited by 116
Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation
Bae, E.-J., Yang, N. Y., Lee, C.-S., Lee, H.-J., Kim, S., Sardi, S. P., & Lee, S. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.128 · Cited by 135
Genetics of neurodegenerative diseases: an overview
Pihlstrøm, L., Wiethoff, S., & Houlden, H. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00022-5 · Cited by 130
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.